• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • MRI Images
  • Sample Access
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

Overview

logo EPAD CohortA key achievement of the EPAD project was the establishment of a Longitudinal Cohort Study (LCS) that has screened over 2,000 participants and collected a wide range of cognitive, clinical, neuroimaging and biomarker data to help further our understanding of the early stages of Alzheimer’s disease. EPAD has made this database open access and publicly available to the research community. On behalf of the EPAD consortium, we hope that the EPAD data will be a significant asset to the worldwide research.

Access

All EPAD data are shared through a secure online Workspace. To access the data, you will need to make an online request…
Read More

Data

Data has been collected from participants across a wide-range of outcomes at each annual visit…
Read More

Samples access

The EPAD Bioresource consists of over 100,000 samples consisting of blood, CSF, saliva and urine…
Read More

MRI Images

This section represents an overview of the MRI data collected throughout the EPAD study…
Read More

The LCS was initiated and the first participant screened in May 2016. Screening into the LCS was stopped on 29 February 2020 and a total of 2,096 participants had been screened. Of these 217 were screen failures and 215 have withdrawn. The number of participants that completed each visit during the study period is outlined in the infographic below.

Screened
2,096
6 month visit
1,596
Year 1 visit
1,225
Year 2 visit
421
Year 3 visit
121

Although the LCS is no longer following up participants, it provides an ongoing legacy through open access to data and a vast range of possibilities for sample access. The impact of EPAD to further our understanding of Alzheimer’s disease via future research generated from global access to data and samples will be substantial.

Datasets available

  • EPAD LCS V500.0
  • EPAD LCS V1500.0
  • EPAD LCS V500.1
  • EPAD LCS V.IMI (It represents all the data collected and processed during the IMI period of EPAD)

About the Workspaces

The analytical database for the LCS was developed and hosted by our partner Aridhia within the Digital Research Environment (DRE, formerly AnalytiXagility). Workspaces in the DRE provided the secure collaboration and data management services to integrated and distribute LCS data. The analytical database includes all of the clinical, cognitive and biomarker measurements of recruited individuals according to the EPAD LCS protocol, collected and curated according to high quality standards. The DRE was also used as part of the EPAD LCS Research Access Process (ERAP) where the DRE hosted metadata to help researchers interpret the database.

“Our data team generate the published snapshots of the analytical database, and publish snapshots and metadata. Researchers can discover the data through publications, Internet searches and go through a partially automated process to request access. A semi-automated process streamlines the review and approval of requests. Data is then usually delivered to a private Workspace in the DRE where they can download the open data, collaborate on analysis and also redeposit derived data back to the LCS.”

Rodrigo Barnes
Aridhia

 

 

Share this page
FacebookTwitterLinkedInGoogle+
Latest News
  • Edinburgh Dementia Prevention Summer School 2022
    2022-06-30
  • EPAD at AAIC22!
    2022-06-30
  • ADDI NeuroToolKit Data Hackathon
    2022-05-17
  • The Neuronet Coordination and Support Action releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies
    2022-05-09
  • First national follow-on study to EPAD LCS launches
    2022-04-07
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

The @AlzData #NeuroToolKit Data Hackathon has started! 45 teams are uing the NTKApp, @IMI_EPAD datasets, and statistical analysis tools available on the #ADWorkbench to investigate the potential clinical utility of different biomarkers in #Alzheimer’s disease. twitter.com/AlzData/status…

reply retweet favorite
10:34 am · 2022-07-04
Twitter
EPAD
EPAD
@IMI_EPAD

The @CenDemPrevent Summer School, a 4-day interactive course on #brainhealth, is designed for clinicians, researchers and students. Space is limited, sign up quickly! 🗓️26-29 September 📍Edinburgh For more info, including programme⤵️ ep-ad.org/edinburgh-deme… pic.twitter.com/FSypbvWK4L

reply retweet favorite
12:38 pm · 2022-06-30
Twitter
EPAD
EPAD
@IMI_EPAD

There’s still time to join the @AlzData #NeuroToolKit #Data Hackathon! Registration closes on 24 June! Participants will work with @IMI_EPAD datasets and utilise the tools on the #ADWorkbench. Interested in participating? ➡️alzheimersdata.org/hackathon twitter.com/IMI_EPAD/statu…

reply retweet favorite
7:21 am · 2022-06-22
Twitter
EPAD
EPAD
@IMI_EPAD

Today, colleagues from @AlzData visited @CenDemPrevent to meet with those involved in various programmes including @IMI_EPAD @AD_PREVENT. Many relevant discussions and great catch-up! #BrainHealth #datasharing #collaboration @craig_ritchie68 @samdansobe @GregorySarah @CindyBirck pic.twitter.com/Mr3trKeuoz

reply retweet favorite
2:43 pm · 2022-06-15
Twitter
EPAD
EPAD
@IMI_EPAD

Have a look on the new @AlzheimerEurope #DementiaInEurope magazine featuring an article on @IMI_EPAD and its collaboration with @AlzData to make our data findable, accessible and reusable. @craig_ritchie68 ⤵️ alzheimer-europe.org/resource… twitter.com/AlzheimerEurop… pic.twitter.com/vLuW3HMLUh

reply retweet favorite
1:09 pm · 2022-06-14
Copyright © 2015-2021 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT